Pegaldesleukin, also known as PEG-IL-2, is a pegylated form of interleukin-2 (IL-2), a cytokine that plays a crucial role in the immune response. The pegylation process involves the attachment of polyethylene glycol (PEG) molecules to the IL-2 protein, which enhances its stability, solubility, and half-life in the bloodstream. This modification allows for prolonged therapeutic effects and reduced immunogenicity compared to unmodified IL-2. Pegaldesleukin is primarily investigated for its potential in cancer immunotherapy, particularly in enhancing the proliferation and activation of T cells and natural killer (NK) cells, which are vital for targeting and eliminating tumor cells. Its mechanism of action involves binding to the IL-2 receptor, promoting immune cell growth and activity. Clinical studies have explored its efficacy in various malignancies, including melanoma and renal cell carcinoma. As with any therapeutic agent, potential side effects may include immune-related reactions, and its use is typically monitored in clinical settings to ensure patient safety and optimal therapeutic outcomes.

Pegaldesleukin

141752-91-2: Pegaldesleukin, also known as PEG-IL-2, is a pegylated form of interleukin-2 (IL-2), a cytokine that plays a crucial role in the immune response. The pegylation process involves the attachment of polyethylene glycol (PEG) molecules to the IL-2 protein, which enhances its stability, solubility, and half-life in the bloodstream. This modification allows for prolonged therapeutic effects and reduced immunogenicity compared to unmodified IL-2. Pegaldesleukin is primarily investigated for its potential in cancer immunotherapy, particularly in enhancing the proliferation and activation of T cells and natural killer (NK) cells, which are vital for targeting and eliminating tumor cells. Its mechanism of action involves binding to the IL-2 receptor, promoting immune cell growth and activity. Clinical studies have explored its efficacy in various malignancies, including melanoma and renal cell carcinoma. As with any therapeutic agent, potential side effects may include immune-related reactions, and its use is typically monitored in clinical settings to ensure patient safety and optimal therapeutic outcomes.

Pegaldesleukin, a PEG-IL2 conjugate, exhibits antiviral properties, potentially slowing HIV progression, preserving immune function.

CAS 141752-91-2

Pegaldesleukin

Pegaldesleukin

Ref: TM-T77141